Savolitinib

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity[1][2].

Product Specifications

CAS Number

[1313725-88-0]

Product Name Alternative

Volitinib; HMPL-504; AZD-6094

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Savolitinib.html

Purity

99.99

Solubility

DMSO : ≥ 20.83 mg/mL

Smiles

CN1N=CC(C2=CN=C3C(N([C@H](C4=CN5C(C=C4)=NC=C5)C)N=N3)=N2)=C1

Molecular Formula

C17H15N9

Molecular Weight

345.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Jia H, et al. Discovery of (S) -1- (1- (Imidazo[1,2-a]pyridin-6-yl) ethyl) -6- (1-methyl-1H-pyrazol-4-yl) -1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57 (18) :7577-89.|[2]Gavine PR, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9 (1) :323-33.